Segluromet
Product Images NDC 50090-6218

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Segluromet (NDC 50090-6218). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906218)

The label for SEGLUROMET 2.5 mg/1000 mg oral tablet, containing ertugliflozin and metformin hydrochloride, from A-S Medication Solutions. The label includes instructions to store the product at 68 to 77 degrees Fahrenheit and protect from moisture. The package contains 60 tablets and provides dosage directions to refer to the package insert. The NDC is 50090-6218-0.*

FDA Label Image

Chemical Structure (Segluromet 01)

Chemical structure of the active ingredient in SEGLUROMET by A-S Medication Solutions, showing detailed molecular bonding and groups including hydroxyl, ethoxy, and carboxylic acid components.*

FDA Label Image

Chemical Structure (Segluromet 02)

Chemical structure diagram of the active ingredient related to SEGLUROMET, showing a molecular formula with labeled atoms and a hydrochloride (HCl) component.*

FDA Label Image

Figure 1 (Segluromet 03)

A forest plot showing the geometric mean ratio with 90% confidence intervals for AUC and Cmax of various drugs (Sitagliptin, Metformin, Glimepiride, Simvastatin, Rifampin) relative to ertugliflozin alone. The horizontal axis represents relative percentage values, with a vertical line at 100% indicating the reference point for ertugliflozin alone.*

FDA Label Image

Figure 2 (Segluromet 04)

A forest plot showing geometric mean ratios (90% confidence intervals) for AUC and Cmax of various single-dose medications, including Sitagliptin 100 mg, Metformin 1000 mg, Glimepiride 1 mg, Simvastatin 40 mg, and Simvastatin Acid, all relative to concomitant medication alone. The chart includes error bars representing confidence intervals and notes that all ertugliflozin doses were given as 15 mg single dose.*

FDA Label Image

Figure 3 (Segluromet 05)

A line graph showing the mean percent change in HbA1c from baseline over 26 weeks for three groups: placebo, Ertugliflozin 5 mg, and Ertugliflozin 15 mg. The x-axis represents weeks, and the y-axis represents the HbA1c percentage change. The graph compares the reduction in HbA1c levels, with the Ertugliflozin groups showing greater decreases than placebo. A table below the graph lists the number of subjects in each group at various weeks.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.